Related Experiment Video
Updated: Jul 4, 2025
Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
Published on: April 29, 2020
Exploring the potential of Toxoplasma gondii in drug development and as a delivery system
Chanjin Yoon1,2, Yu Seong Ham1,3, Woo Jin Gil1,3
1Department of Molecular and Life Science, Hanyang University, Ansan, 15588, South Korea.
Abstract:
Immune-mediated inflammatory diseases are various groups of conditions that result in immune system disorders and increased cancer risk. Despite the identification of causative cytokines and pathways, current clinical treatment for immune-mediated inflammatory diseases is limited. In addition, immune-mediated inflammatory disease treatment can increase the risk of cancer. Several previous studies have demonstrated that Toxoplasma gondii manipulates the immune response by inhibiting or stimulating cytokines, suggesting the potential for controlling and maintaining a balanced immune system. Additionally, T. gondii also has the unique characteristic of being a so-called "Trojan horse" bacterium that can be used as a drug delivery system to treat regions that have been resistant to previous drug delivery therapies. In this study, we reviewed the potential of T. gondii in drug development and as a delivery system through current research on inflammation-regulating mechanisms in immune-mediated inflammatory diseases.
Insights
Toxoplasma gondii shows potential for treating immune-mediated inflammatory diseases by modulating immune responses. This parasite can also act as a Trojan horse for targeted drug delivery, overcoming resistance issues.
Area of Science:
- Immunology
- Parasitology
- Drug Development
Background:
- Immune-mediated inflammatory diseases (IMIDs) involve immune system dysfunction and elevate cancer risk.
- Current IMID treatments are limited and can paradoxically increase cancer susceptibility.
- The parasite Toxoplasma gondii influences host immune responses, offering potential therapeutic avenues.
Purpose of the Study:
- To review the therapeutic potential of Toxoplasma gondii in drug development.
- To explore T. gondii as a novel drug delivery system for IMIDs.
- To examine T. gondii's role in regulating inflammation.
Main Methods:
- Literature review of current research on T. gondii and IMIDs.
- Analysis of T. gondii's immunomodulatory mechanisms.
- Evaluation of T. gondii as a drug delivery vehicle.
Main Results:
- T. gondii can inhibit or stimulate cytokines, rebalancing immune responses.
- T. gondii serves as a 'Trojan horse' for drug delivery to resistant sites.
- Research highlights T. gondii's potential in managing inflammation.
Conclusions:
- Toxoplasma gondii presents a dual potential in treating IMIDs: immune modulation and targeted drug delivery.
- Further research into T. gondii-based therapies could overcome limitations of current treatments.
- Harnessing T. gondii may offer innovative strategies for immune-mediated diseases and cancer risk reduction.
Related Concept Videos
01:28Preclinical Development: Overview
01:16Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...